Helen Sabzevari
President & Chief Executive Officer Precigen
Dr. Helen Sabzevari is President and CEO of Precigen, a Maryland-based commercial-stage biopharmaceutical company, and member of the Precigen Board of Directors. She brings extensive expertise in research and development of immunotherapy-based therapeutics and experience translating novel treatments from pre-clinical stage into the clinic. Previously, she co-founded and served as Chief Scientific Officer of Compass Therapeutics and held leadership roles in Immuno-Oncology and Global Research and Early Development at Merck KGaA/EMD Serono. Dr. Sabzevari received her doctorate degree in cell and molecular immunology and completed her postdoctoral work at the Scripps Research Institute.
Seminars
Thursday 17th September 2026
Panel Discussion: Accelerating Veinto-Vein Time through Innovative QC Testing Strategies
2:35 pm
- Exploring rapid sterility testing methods, including ATP release assays and NGS-based microbial detection, to reduce traditional 7-day timelines
- Implementing rapid QC testing to accelerate vein-to-vein time without compromising safety and regulatory compliance
- Highlighting emerging technologies demonstrating rapid, reliable testing to support clinical and commercial qc workflows
Wednesday 16th September 2026
Developing the UltraCAR-T® Platform to Expand Patient Access & Drive Scalable Manufacturing in Next-Generation Cell Therapy
9:50 am
